DEF 14A: BioRestorative Therapies Seeks Stockholder Approval for Director Election, Stock Incentive Plan Amendment, and Auditor Ratification

BioRestorative Therapies is holding its annual meeting on September 19, 2024, to vote on the election of a director, an amendment to the stock incentive plan, and the ratification of its independent auditor.

Summary

• BioRestorative Therapies, Inc. will hold its Annual Meeting of Stockholders on September 19, 2024.
• Stockholders will vote on three proposals: electing one Class I director, approving an amendment to the 2021 Stock Incentive Plan to increase the authorized shares from 3,850,000 to 6,850,000, and ratifying the selection of Marcum LLP as the independent auditor for the fiscal year ending December 31, 2024.
• The record date for determining stockholders eligible to vote is August 1, 2024.
• The company plans to mail the Notice of Internet Availability of Proxy Materials by August 9, 2024.
• As of August 1, 2024, there were 6,919,919 shares of common stock outstanding and entitled to vote.
• Additionally, there were 1,398,158 shares of Series B preferred stock outstanding, but these shares are not currently convertible or entitled to vote due to beneficial ownership limitations.
• The company's executive compensation includes salary, bonus, stock awards, and option awards.
• For 2023, the CEO's total compensation was $1,254,167, while the average compensation for non-CEO NEOs was $911,146.
• The company's Board of Directors consists of Lance Alstodt, Francisco Silva, Nickolay Kukekov, Patrick F. Williams, and David Rosa.
• Dr. Kukekov is up for election as a Class I director to serve until the 2027 Annual Meeting.
• The Board recommends voting FOR the director nominee, the amendment to the stock incentive plan, and the ratification of the independent auditor.

Sentiment

Score: 6

Explanation: The document is primarily informational, outlining the proposals for the annual meeting. While there are some negative aspects, such as the company's net losses, the overall tone is neutral.

Positives

• The Board of Directors is actively engaged in risk oversight through its committees.
• The Audit Committee is comprised of independent directors and has a written charter available on the company's website.
• The company has a Code of Business Conduct and Ethics for senior financial officers, which is posted on its website.
• The Board recommends voting FOR all proposals.

Negatives

• The Series B preferred stock is not currently convertible or entitled to vote due to beneficial ownership limitations, potentially impacting the influence of the holder, Auctus Fund, LLC.
• The company experienced net losses of $(10,417,704), $(13,222,296), and $(44,303,295) in 2023, 2022, and 2021, respectively.
• Executive compensation is high relative to the company's net losses.

Risks

• The company's future success depends on attracting and retaining key employees, consultants, and advisors, which is supported by the Stock Incentive Plan.
• Failure to obtain stockholder approval for the amendment to the Stock Incentive Plan could hinder the company's ability to attract and retain talent.
• The Beneficial Ownership Limitation on the Series B preferred stock could impact the influence of the holder, Auctus Fund, LLC.
• The company's reliance on key personnel, such as Lance Alstodt and Francisco Silva, presents a risk if they were to leave the company.

Future Outlook

The company aims to attract and retain employees and align their interests with those of stockholders through the Stock Incentive Plan.

Management Comments

• Lance Alstodt, Chief Executive Officer, encourages stockholders to submit their proxy or voting instructions as soon as possible.
• The Board believes that Mr. Alstodt's combined role as Chief Executive Officer and Chairman of the Board enables the company to benefit from his institutional and industry knowledge.

Industry Context

The document does not provide specific details on how this announcement relates to broader industry trends or competitors. However, the election of directors and the approval of the stock incentive plan are standard corporate governance practices.

Comparison to Industry Standards

• The document does not provide enough information to make a detailed comparison to industry standards.
• Executive compensation structures, including salary, bonus, and equity awards, are common in publicly traded companies, particularly in the biotechnology and pharmaceutical sectors.
• Companies like Amgen, Gilead Sciences, and Biogen have similar compensation components for their executives.
• The size and structure of the stock incentive plan are also typical for companies seeking to attract and retain talent in competitive industries.

Related Party Transactions

• The document mentions that related party transactions are reviewed by the Board of Directors on a case-by-case basis.

Stakeholder Impact

• Approval of the stock incentive plan amendment could positively impact employees by providing them with additional equity-based compensation.
• The election of directors will impact the composition of the Board and its oversight of the company.
• The ratification of the independent auditor ensures the integrity of the company's financial reporting.

Next Steps

• Stockholders should review the proxy materials and vote on the proposals.
• The company will hold its Annual Meeting of Stockholders on September 19, 2024.
• The company will continue to operate under the direction of its Board of Directors and executive management.

Key Dates

Keywords

proxy statement, annual meeting, stockholders, director election, stock incentive plan, auditor ratification, executive compensation, Marcum LLP, BioRestorative Therapies